Drug General Information (ID: DDIB76V0PW)
Drug Name			Meloxicam		Drug Info		Tolevamer		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Nsaids/Analgesics				Potassium-Binding Resin
Structure

Mechanism of Meloxicam-Tolevamer Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Meloxicam				Tolevamer
Mechanism		Meloxicam containing sorbitol				Increase the risk of intestinal necrosis in combination with sorbitol
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Meloxicam and Tolevamer

Recommended Action
Management		Until more information is available, the concurrent use of sorbitol as a vehicle or otherwise should generally be avoided in patients receiving polystyrene sulfonate exchange resins.

References
1	Product Information. Kayexalate (sodium polystyrene sulfonate). Sanofi Winthrop Pharmaceuticals, New York, NY.
2	Product Information. Mobic (meloxicam) Boehringer-Ingelheim, Ridgefield, CT.
3	Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM "Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis." Surgery 101 (1987): 267-72. [PMID: 3824154]